Conference Coverage

VIDEO: EULAR guidance on DMARD use in RA made ‘more concise’


 

AT THE EULAR 2016 CONGRESS

References

The recommendations are currently in draft format and once finalized they will be published in Annals of the Rheumatic Diseases and also made freely available via the EULAR website, joining the organization’s many other recommendations for the management of rheumatic diseases. Dr. Smolen noted that these are intended as a template to provide national societies, health systems, and regulatory bodies a guide to the best evidence-based use of DMARDS in RA throughout Europe.

Dr. Smolen has received grant support and/or honoraria for consultations and/or for presentations from: AbbVie, Amgen, AstraZeneca, Astro-Pharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, ILTOO Pharma, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, and UCB.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Pages

Recommended Reading

Registry study adds evidence for use of DMARD combo first in early RA
MDedge Internal Medicine
Analysis provides key questions – and answers – regarding future of JAK inhibitors for RA
MDedge Internal Medicine
Early RA remission more unstable in the presence of foot synovitis
MDedge Internal Medicine
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
MDedge Internal Medicine
Remicade to infliximab biosimilar switches fare well in real-life practice
MDedge Internal Medicine
Make informed treatment decisions about biosimilars
MDedge Internal Medicine
Anti-TNF certolizumab pegol effective in early RA
MDedge Internal Medicine
Hydroxychloroquine, abatacept linked with reduced type 2 diabetes
MDedge Internal Medicine
VIDEO: Smoking, excess weight hinder sustained remission in early RA
MDedge Internal Medicine
Simplify cardiac risk assessment for rheumatologic conditions
MDedge Internal Medicine

Related Articles